Maria Grazia Bendini
Research Subjects
Research Interests
Maria Grazia Bendini has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Andrea Giordano
1 shared publication- Andrea Mazza
Hospital Santa Maria della Stella , Orvieto , Italy
1 shared publication Emanuela Moriconi
1 shared publicationGaetano Antonio Lanza
1 shared publicationGiampiero Giordano
1 shared publicationGiulio Menichini
1 shared publication
Latest Publications
- 1 March 2007
- Vol. 8 (3) , 148-60
[Risk factors for cardiovascular diseases: what is the role for homocysteine?].
Cardiovascular diseases are commonly related to classical risk factors, but other risk markers have been identified, including homocysteine. Homocysteine is a sulphurated amino acid which derives from methionine. The causes of hyperhomocysteinemia are multifactorial, such as genetic defects, pathophysiological conditions, lifestyle and drugs-related. Hyperhomocysteinemia favors atherothrombosis through endothelial dysfunction, enhancement of inflammation and thrombophilic profile. A number of clinical and laboratory trials exist regarding the association between homocysteine levels and an increased risk of cardiovascular disease. However, the lack of homogeneity in the data, together with the high number of factors capable of influencing homocysteine plasma levels, and the disappointing results of therapeutic trials do not permit us at present to consider homocysteine as an independent and major risk factor for cardiovascular disease.
- 1 March 2007
- Vol. 8 (3) , 148-60
[Risk factors for cardiovascular diseases: what is the role for homocysteine?].
Cardiovascular diseases are commonly related to classical risk factors, but other risk markers have been identified, including homocysteine. Homocysteine is a sulphurated amino acid which derives from methionine. The causes of hyperhomocysteinemia are multifactorial, such as genetic defects, pathophysiological conditions, lifestyle and drugs-related. Hyperhomocysteinemia favors atherothrombosis through endothelial dysfunction, enhancement of inflammation and thrombophilic profile. A number of clinical and laboratory trials exist regarding the association between homocysteine levels and an increased risk of cardiovascular disease. However, the lack of homogeneity in the data, together with the high number of factors capable of influencing homocysteine plasma levels, and the disappointing results of therapeutic trials do not permit us at present to consider homocysteine as an independent and major risk factor for cardiovascular disease.